May 3, 2018 / 6:01 AM / 22 days ago

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

May 3 (Reuters) - Mithra Pharmaceuticals SA:

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

* MITHRA ALSO ANNOUNCES THAT ENDOMETRIAL SAFETY SUBSTUDY HAS COMPLETED RECRUITMENT

* ESTELLE PHASE III STUDIES REMAIN ON TRACK TO REPORT TOP-LINE RESULTS IN Q3 2018 FROM EUROPE/RUSSIA AND Q1 2019 FROM US/CANADA

* IN US/CANADIAN STUDY LAST SUBJECT VISIT IS EXPECTED TO TAKE PLACE IN Q4 2018

* PHASE III EUROPEAN/RUSSIAN STUDY OF ESTELLE® SEEN LOWER THAN EXPECTED DROP-OUT RATE WITH OVER 1,200 WOMEN COMPLETING MIN. 13-CYCLES OF TREATMENT FROM 1,577 WOMEN RECRUITED

* ENDOMETRIAL SAFETY SUBSTUDY ON TRACK TO REPORT TOP LINE RESULTS IN Q3 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below